Видео ютуба по тегу Trial: Codebreak 200

CodeBreak 200 | Sotorasib | A Negligent trial that violated randomization!
CodeBreak 200 | Sotorasib | A Negligent trial that violated randomization!
CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC
CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC
#ESMO22 Highlights on Sotorasib in NSCLC with KRAS G12C mutation: The CodeBreaK 200 study
#ESMO22 Highlights on Sotorasib in NSCLC with KRAS G12C mutation: The CodeBreaK 200 study
CodeBreaK 200 phase III study - Additional remarks from Melissa L. Johnson during press briefing
CodeBreaK 200 phase III study - Additional remarks from Melissa L. Johnson during press briefing
Overall survival in the Phase II CodeBreaK 100 trial in NSCLC
Overall survival in the Phase II CodeBreaK 100 trial in NSCLC
Sotorasib shows as a tolerable treatment option for patients with KRASG12C-mutated advanced NSCLC
Sotorasib shows as a tolerable treatment option for patients with KRASG12C-mutated advanced NSCLC
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung canc...
Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung canc...
Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC
Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
Sotorasib shows superior PFS and ORR compared to docetaxel for NSCLC
KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer
KRYSTAL-1 and CodeBreak 100: targeting KRAS G12C in lung cancer
CodeBreak 100: sotorasib in KRAS-mutated NSCLC
CodeBreak 100: sotorasib in KRAS-mutated NSCLC
KRAS-mutant NSCLC: CodeBreak 100 trial of sotorasib
KRAS-mutant NSCLC: CodeBreak 100 trial of sotorasib
Treatment strategies for KRAS-mutant NSCLC with co-mutations
Treatment strategies for KRAS-mutant NSCLC with co-mutations
What are the latest developments in KRAS-mutant NSCLC?
What are the latest developments in KRAS-mutant NSCLC?
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC
CodeBreaK 100: Patient-reported outcomes evaluating sotorasib in KRAS p.G12C mNSCLC
KRAS G12C Inhibitors Versus Chemotherapy in Second Line - Targeted Therapies in Lung Cancer 2023
KRAS G12C Inhibitors Versus Chemotherapy in Second Line - Targeted Therapies in Lung Cancer 2023
ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-Fontecedro
ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-Fontecedro
ESMO highlights: KRAS G12C inhibitors
ESMO highlights: KRAS G12C inhibitors
Key lung cancer updates: KRAS(G12C) inhibitors and ADCs
Key lung cancer updates: KRAS(G12C) inhibitors and ADCs
Биткоин (BTC) , Index Crypto 20 - обзор криптовалют от 8.04.2025 | Роман Андреев
Биткоин (BTC) , Index Crypto 20 - обзор криптовалют от 8.04.2025 | Роман Андреев